NCT06605872Completed
DigiDiab Pilot: Impact Study Hospital
An Open, Multicentre, Prospective, Non-interventional Study of the CE-marked Medical Device GlucoTab, According to Intended Use Without Additional Invasive and Stressful Measures With a Matched Retrospective Control Group
Source: ClinicalTrials.gov · Last updated 7 Oct 2026
Brief summary (registry, in English)
GlucoTab is an innovative workflow and decision support tool for standardised diabetes management by healthcare professionals which provides automated and personalised dosage recommendations for different insulin therapy regimens.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 731 (actual)
- First submitted
- 18 Sept 2024
- Start date
- 1 Apr 2025
- Primary completion date
- 15 Jan 2026
- Lead sponsor
- Medical University of Graz
- Diseases
- Type 2 diabetes
- NCT number
- NCT06605872
What you commit to
- Study type: Observational
- Participants enrolled: 731
- From 1 Apr 2025 to the primary completion date, 15 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- intravenous insulin therapy
- hyperglycaemic episodes (ketoacidosis, hyperosmolar state) if they require intravenous insulin therapy
Other illness
- type 1 diabetes mellitus
- gestational diabetes or pregnancy
- known or suspected allergy to insulin
- any mental condition rendering the patient incapable of giving his/her consent
- any disease or condition which according to the investigator or treating physician would interfere with the trial or the safety of the patient
- Inclusion and exclusion criteria will be the same as above for the retrospective CG with the exception of:
Other
- continuous subcutaneous insulin infusion
- total parenteral nutrition
- period of time will be from September 2022 to September 2023
- no informed consent will be obtained from the retrospective CG
Who the study is looking for
- informed consent obtained after being advised of the nature of the study
- a documented history of type 2 diabetes prior to inclusion or new-onset hyperglycaemia which requires s.c. insulin therapy during hospital stay
- admission to either surgical or internal medicine ward
- an expected length of hospital stay for at least 48 hours after enrolment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitari Joan XXIII de Tarragona Coordinator of this site? Confirm its status | Tarragona | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.